Iconic Therapeutics
Iconic Therapeutics developed tissue-factor-targeting medicines for retinal disease, cancer and inflammatory disorders. It became a wholly owned subsidiary of Endpoint Health in 2022.
Key facts
| Company Operating Status | Acquired |
|---|---|
| Full Address | 701 Gateway Blvd Suite 100, South San Francisco, CA 94080 |
| Wellfound ID | iconic-therapeutics |
Contact details
Email and phone for Iconic Therapeutics are available to signed-in members of CliffBio.
Sign in to view